In the retinal disease area in the second quarter of this year, the European Commission granted orphan medicinal product designation to ADX-2191 for the treatment of retinal detachment, opening a new market opportunity for ADX-2191 in the European Union as drugs receiving the orphan medicinal product designation are eligible to protocol assistance, research funding and upon approval, 10 years of EU market exclusivity.
Refer to the input text as context and select the correct relationship between 'EU' and 'European Union' from the available options.
Options: business division, operator, member of, location of formation